LNTH:NAS (USA) Also trade in: Germany

Lantheus Holdings Inc

$ 24.15 0.25 (1.05%)
Volume: 209,938 Avg Vol (1m): 398,391
Market Cap $: 932.88 Mil Enterprise Value $: 1.09 Bil
P/E (TTM): 23.22 P/B: 13.47
Earnings Power Value 17.72
Net Current Asset Value -4.38
Tangible Book 1.17
Projected FCF 5.92
Median P/S Value 13.48
Graham Number 5.22
Peter Lynch Value 19.41
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.43
Equity-to-Asset 0.16
Debt-to-Equity 3.75
Debt-to-EBITDA 3.29
Interest Coverage 3.75
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.65
DISTRESS
GREY
SAFE
Beneish M-Score -2.63
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 24.07%
WACC 13.34%

Profitability & Growth : 5/10

Current vs industry vs history
Operating Margin % 19.03
Net Margin % 11.80
ROE % 88.86
ROA % 9.92
ROC (Joel Greenblatt) % 50.12
3-Year Total Revenue Growth Rate 5.40
3-Year Total EBITDA Growth Rate 20.20

» LNTH's 30-Y Financials

Financials (Next Earnings Date: 2019-04-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:LNTH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare BSP:AALR3 SZSE:300289 NAS:HSKA NAS:VIVO LSE:IDHC NAS:NEO NAS:RDNT NAS:NTRA SHSE:603716 NAS:SRDX NSE:THYROCARE SZSE:300639 NYSE:ARA TSE:2309 OSTO:CEVI AMEX:SENS XBRU:BCART HKSE:02393 NAS:NRCIA NYSE:NVTA
Traded in other countries 0L8.Germany
Address 331 Treble Cove Road, North Billerica, MA, USA, 01862
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacies and directly to hospitals and clinics predominantly in the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 23.22
Forward PE Ratio 20.92
N/A
PE Ratio without NRI 23.22
Price-to-Owner-Earnings 26.89
PB Ratio 13.47
PS Ratio 2.78
Price-to-Free-Cash-Flow 23.20
Price-to-Operating-Cash-Flow 15.57
EV-to-EBIT 16.22
EV-to-EBITDA 13.43
EV-to-Revenue 3.16
PEG Ratio 0.69
Current Ratio 3.70
Quick Ratio 3.08
Days Inventory 68.12
Days Sales Outstanding 46.51
Days Payable 38.90

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -9.20

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 20.73
Price-to-Projected-FCF 4.07
Price-to-Median-PS-Value 1.81
Price-to-Peter-Lynch-Fair-Value 1.25
Price-to-Graham-Number 4.64
Earnings Yield (Joel Greenblatt) % 6.17
Forward Rate of Return (Yacktman) % 21.28

More Statistics

Revenue (TTM) (Mil) $ 343.37
EPS (TTM) $ 1.04
Beta 1.82
Volatility % 60.7
52-Week Range $ 12.59 - 26.3
Shares Outstanding (Mil) 38.63

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N